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A B S T R A C T   
Background and aims: Sex differences in cardiovascular prevention have been reported, yet the role of sex with 
regard to different modifiable risk factors such as low-density lipoprotein cholesterol (LDL-C), systolic blood 
pressure (BP), and glycated hemoglobin (HbA1c) in primary care settings is unclear. Therefore, we studied sex 
differences in assessment and measured values of LDL-C, BP, and HbA1c in primary and secondary cardiovas-
cular prevention delivered by general practitioners. 
Methods: This cross-sectional study was based on electronic medical records of 59,092 primary care patients 
(51.9% women) aged 40–79 years in Switzerland. Multilevel regression was used to model associations of sex 
with assessment and measured values of LDL-C, BP, and HbA1c in 2018. 
Results: In both primary and secondary prevention, women had lower LDL-C assessment rates (age-adjusted odds 
ratio (aOR) 0.71 [95% confidence interval (CI) 0.67 to 0.75] and 0.70 [CI 0.51 to 0.95]), and higher measured 
LDL-C values than men (age-adjusted difference 0.30 mmol/L [CI 0.25 to 0.35] and 0.28 mmol/L [CI 0.07 to 
0.48]). Compared with men, women in primary prevention displayed lower BP and HbA1c assessment fre-
quencies (aOR 0.77 [CI 0.73 to 0.81] and 0.76 [CI 0.71 to 0.80]) and measured values (age-adjusted difference 
-2.49 mmHg [CI -2.99 to -1.79] and -0.19% [CI -0.24 to -0.14]), while there was no sex difference in secondary 
prevention. Age-dependent increases in measured values of LDL-C, BP, and HbA1c were greater in women than 
men. 
Conclusions: Control of LDL-C in women in primary care should be improved to reduce sex-based inequalities in 
prevention of cardiovascular disease.   
1. Introduction 
Cardiovascular disease (CVD) is the leading cause of death and loss of 
quality-adjusted life years in women and men alike [1,2]. Cardiovas-
cular risk is driven by both non-modifiable risk factors, particularly age 
[3], as well as modifiable risk factors, some being amenable to phar-
macologic therapy, such as elevated low-density lipoprotein cholesterol 
(LDL-C), blood pressure (BP), and glycated hemoglobin (HbA1c) [4]. 
Interestingly, age differently affects CVD development in women and 
men: before menopause, women are largely protected from CVD because 
of the cholesterol-lowering, vasodilator, anti-inflammatory, and 
anti-diabetic effects of endogenous estrogens [5]. After menopause, the 
prevalence of modifiable risk factors increases, which may explain why 
women develop CVD about 8 years later in life than men [6]. 
CVD prevention strategies, including assessment and treatment of 
modifiable risk factors, are equally effective in women and men in 
reducing cardiovascular morbidity and mortality [7–9]. However, 
women in both primary prevention (i.e., patients considered at risk for 
CVD) and secondary prevention (i.e., patients with established CVD) are 
less likely than men to have individual cardiovascular risk factors 
assessed [10–12]. Moreover, some studies indicated that fewer women 
received appropriate preventive medications and achieved target values 
for LDL-C, systolic BP, or HbA1c than men [10,11,13,14], while others 
found no differences [15]. However, many previous investigations did 
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not study patients in both primary and secondary prevention [11,13], 
derived data from randomized trials [10] or were otherwise not based on 
primary care settings [12], and there is only limited information on 
European patients currently available. Moreover, it is unclear whether 
sex differences disproportionately apply to distinct modifiable risk fac-
tors, which may have important implications for improving cardiovas-
cular care. Therefore, we used a large Swiss primary care cohort to 
compare age-dependent differences between women and men in 
assessment, measured values and treatment of LDL-C, BP, and HbA1c in 
contemporary primary and secondary prevention of CVD. 
2. Patients and methods 
2.1. Design, setting and participants 
This retrospective, cross-sectional study is based on electronic 
medical records provided by the Family Medicine International Classi-
fication of Primary Care Research using Electronic Medical Records 
(FIRE) project, which has been described previously [16]. Briefly, the 
FIRE database collects data from electronic medical records of currently 
over 500 general practitioners in Switzerland. Records contain patient 
demographics, laboratory measurements, vital signs, drug prescriptions 
and diagnosis codes based on the 2nd edition of the International 
Classification of Primary Care (ICPC-2) [17]. 
We extracted information of patients aged 40–79 years with at least 
two consultations, one before 2017 and one during 2018, to ensure that 
sufficient baseline data was available to study preventive measures. We 
retrieved information on age, sex, CVD history, cardiovascular risk 
category [18,19] (Supplementary Table 1), the number of consultations, 
the number of LDL-C, BP, and HbA1c measurements, as well as the latest 
recorded values of LDL-C, high-density lipoprotein cholesterol (HDL-C), 
total cholesterol, triglycerides, systolic BP, diastolic BP, and HbA1c in 
2018. We also extracted drug prescriptions for the treatment of dysli-
pidemia, hypertension, and diabetes [20] (Supplementary Table 2). For 
statins, we retrieved daily doses of the latest prescription in 2018 and 
calculated the treatment intensity [21]. Based on absence or presence of 
a CVD history, patients were classified into primary or secondary pre-
vention (Supplementary Table 3 and Supplementary Figure 1). Patients 
with a first CVD diagnosis in 2018 were excluded to avoid confounding 
of the primary and secondary prevention groups. 
Data acquisition and analyses have been approved by the local ethics 
committee (BASEC-Nr. Req-2017-00797) and are in accordance with the 
World Medical Association Declaration of Helsinki and with good clin-
ical practice guidelines. The ethics committee waived the requirement to 
obtain patients’ informed consent. 
2.2. Statistical analyses 
All statistical analyses were performed using R software version 3.4.0 
[22]. To describe the data, we used counts and proportions (n and %) or 
medians with interquartile ranges. Group comparisons were carried out 
using Wilcoxon rank-sum tests, Chi-squared tests, or Poisson regression, 
as appropriate. We assumed significance for p < 0.05. To study assess-
ment and measured values of LDL-C, BP, and HbA1c, respectively, we 
adopted multilevel regression models, accounting for the hierarchical 
structure of the data with patients being clustered within general prac-
titioners. Assessment of LDL-C, BP, and HbA1c was modeled with lo-
gistic regression (assessed vs. not assessed), and linear regression was 
used to model the measured values. All regression analyses were carried 
out separately for patients in primary and secondary prevention. Pre-
selected fixed effect variables were patient sex and age (centered, also as 
quadratic term), with interactions. For the LDL-C values of patients in 
primary prevention, we repeated the analysis with stratification for 
cardiovascular risk categories [18]. We added bootstrap 95% confidence 
intervals (CI) to predicted values, using the add_ci() function from the R 
package ciTools (2000 simulations, disregarding random effects). To 
translate estimated interaction coefficients into effect sizes with CIs and 
p values for multiple comparisons, we used the glht() function from the R 
package multcomp. Results are reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines. 
3. Results 
3.1. Study population 
We studied 59,092 patients of 167 general practitioners from 62 
practices: 95.9% (n = 56,694) in primary prevention and 4.1% (n =
2,398) in secondary prevention (Supplementary Figure 1). Patient 
characteristics of women and men in primary and secondary prevention 
are given in Table 1. 
3.2. Assessment of LDL-C, BP, and HbA1c 
In primary prevention, LDL-C, BP, and HbA1c were less frequently 
assessed in women than in men (age-adjusted odds ratio (aOR) 0.71 
[95% CI 0.67 to 0.75], 0.77 [95% CI 0.73 to 0.81], and 0.76 [95% CI 
0.71 to 0.81], respectively), but assessment proportions increased with 
age in both sexes. In secondary prevention, only LDL-C was less 
frequently assessed in women than in men (aOR 0.70 [95% CI 0.51 to 
0.95]), and this was independent of age (Fig. 1, Table 1 and Supple-
mentary Table 4). In contrast, BP and HbA1c assessment proportions in 
secondary prevention were not associated with sex but increased with 
age. With regard to concomitance of LDL-C, BP, and HbA1c assessments, 
men were more likely to have two or all three risk factors measured, 
whereas women were more likely to have only one or none of the risk 
factors assessed in both primary and secondary prevention (Table 1). 
3.3. Measured values and treatment of LDL-C 
3.3.1. Sex differences in values and treatment 
LDL-C levels were higher in women than in men both in primary 
prevention (median 3.2 mmol/L vs. 3.0 mmol/L, age-adjusted difference 
0.30 mmol/L [95% CI 0.25 to 0.35]) and secondary prevention (median 
2.3 mmol/L vs. 2.0 mmol/L, age-adjusted difference 0.28 mmol/L [95% 
CI 0.07 to 0.48]) (Fig. 2A, Table 2 and Supplementary Table 5). The 
difference in primary prevention persisted when patients were stratified 
according to cardiovascular risk categories (Supplementary Figure 2 and 
Supplementary Table 5). Women in both primary and secondary pre-
vention were less often treated with lipid-modifying drugs and received 
less high-intensity treatment than men (Table 2). 
3.3.2. Age dependence of values 
Age differently affected LDL-C levels by sex in primary prevention 
(Fig. 2A and Supplementary Table 5): In women, LDL-C levels increased 
until age 60 years and then decreased, whereas in men, LDL-C levels 
decreased roughly by 0.2 mmol/L per 10 years. The two curves inter-
sected at approximately age 50 years, indicating that LDL-C levels were 
higher in women than in men older than 50 years (predicted difference 
0.4 mmol/L at age 70 years, for instance). Age did not significantly affect 
LDL-C levels in secondary prevention, independent of sex. 
3.4. Measured values and treatment of BP 
3.4.1. Sex differences in values and treatment 
Systolic BP was slightly lower in women than in men in primary 
prevention (median 131 mmHg vs. 134 mmHg, age-adjusted difference 
-2.34 mmHg [95% CI -2.99 to -1.79]) (Fig. 2B, Table 3 and Supple-
mentary Table 5), while there was no significant age-adjusted sex dif-
ference in secondary prevention (median 136 mmHg vs. 134 mmHg). 
Similarly, women in primary but not in secondary prevention were less 
often treated with antihypertensive drugs (Table 3). 
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3.4.2. Age dependence of values 
Systolic BP increased approximately linearly with age, with sex- 
dependent intercepts and slopes (Fig. 2B). In primary prevention, sys-
tolic BP in women was 121 mmHg at age 40 years (predicted) and 
increased by 5 mmHg per 10 years of age, whereas in men, it was 129 
mmHg at age 40 years (predicted) and increased by 3 mmHg per 10 
years of age (Supplementary Table 5). The two curves intersected at age 
70–75 years. In secondary prevention, systolic BP in women was 125 
mmHg at age 40 years (predicted) and increased by 4 mmHg per 10 
years of age, whereas in men, it was 127 mmHg at age 40 years (pre-
dicted) and increased by 2 mmHg per 10 years of age (Supplementary 
Table 5). 
3.5. Measured values and treatment of HbA1c 
3.5.1. Sex differences in values and treatment 
HbA1c values were slightly lower in women compared to men in 
primary prevention (median 5.6% vs. 5.7%, age-adjusted difference 
-0.19% [95% CI -0.24 to -0.14]) (Fig. 2C, Table 4 and Supplementary 
Table 5). In contrast, there was no age-adjusted sex difference in sec-
ondary prevention (median 5.9% vs. 6.0%). Similarly, women in pri-
mary but not in secondary prevention were less often treated with 
antidiabetic drugs (Table 4). 
3.5.2. Age dependence of values 
In primary prevention, HbA1c increased approximately linearly with 
age from 5.5% at age 40 years (predicted) by 0.14% per 10 years in 
women, and from 5.8% at age 40 years (predicted) by 0.09% per 10 
years in men (Fig. 2C and Supplementary Table 5). In secondary pre-
vention, HbA1c values were not associated with age. 
4. Discussion 
The majority of cardiovascular events can be prevented by targeting 
modifiable risk factors both in women and men [7–9]. Nevertheless, in 
this large contemporary cohort of about 60,000 primary care patients, 
we found that women had lower age-adjusted LDL-C assessment rates, 
higher LDL-C levels, and less intensive lipid-lowering treatment in both 
primary and secondary prevention. In contrast, assessment and values of 
BP and HbA1c were lower in women than men in primary prevention, 
while there was no difference in secondary prevention. These findings 
indicate that control of LDL-C in women is disproportionally inferior 
compared to other modifiable risk factors. 
In our study, LDL-C values were considerably higher in women older 
than 50 years, even in patients at very high risk of cardiovascular events. 
In fact, LDL-C differed by 0.3 mmol/L overall and by 0.4 mmol/L at age 
70 years in both primary and secondary prevention. This is concerning 
given that a 1 mmol/L reduction in LDL-C lowers the 5-year incidence of 
major cardiovascular events by approximately 20% in women and men 
alike [23,24]. In contrast to LDL-C, BP and HbA1c values were slightly 
lower in women than men in primary prevention and similar in sec-
ondary prevention. Accordingly, BP and HbA1c were less frequently 
assessed and treated in women than men in primary prevention, while 
there was no difference in secondary prevention. Interestingly, these 
findings from patients in primary prevention suggest that the overall risk 
of elevated systolic BP and HbA1c was lower in women than men aged 
40–79 years, even though it increased more profoundly with age in 
women. In contrast to LDL-C, the patients’ sex played no major role in 
the general practitioners’ decision to assess and control BP and HbA1c in 
secondary prevention. Overall, whereas BP and HbA1c were well 
controlled, LDL-C levels were above recommended treatment goals in 
secondary prevention [8,9]. Our findings are supported by studies 
indicating inferior control of LDL-C [12–14,25] as well as by 
Table 1 
Sex-dependent risk factor assessment in primary and secondary prevention.   
Primary prevention Secondary prevention 
Women Men p value Women Men p value 
n 29,967 26,727  696 1,702  
Age, years 57 (49–68) 57 (49–67) 0.442a 71 (63–76) 68 (60–74) <0.001a 
Cardiovascular risk categoryb, %   <0.001c   N/A 
Low-moderate 81.3 76.5  N/A N/A  
High 10.6 10.5  N/A N/A  
Very high 8.1 13.0  100 100  
Number of annual consultations 4 (2–9) 4 (2–8) <0.001d 8 (4–14) 8 (4–13) <0.001d 
LDL-C assessment, %   <0.001c   0.001c 
No measurement 77.2 71.8  55.5 46.5  
1 measurement 19.6 24.2 33.9 40.8  
≥2 measurements 3.1 4.0 10.6 12.7  
BP assessment, %   <0.001c   0.888c 
No measurement 56.9 53.0  32.2 30.8  
1 measurement 25.4 27.7  26.1 25.8  
≥2 measurements 17.7 19.4  41.7 43.4  
HbA1c assessment, %   <0.001c   0.213c 
No measurement 77.0 73.6  58.8 53.6  
1 measurement 15.3 16.5  21.8 23.0  
≥2 measurements 7.6 9.9  19.4 23.4  
Concomitant assessment of LDL-C, BP, and HbA1c, %  <0.001c   0.013c 
All 3 assessed 10.2 14.6  26.4 30.8  
2 assessed 15.6 16.3  22.7 26.3  
1 assessed 27.0 25.3  28.9 24.0  
None assessed 47.2 43.8  22.0 18.9  
BP, blood pressure; HbA1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol. 
a Data are median (interquartile range) and analyzed using the Wilcoxon rank-sum test. 
b Cardiovascular risk was categorized as described [18,19], with very high risk indicating established cardiovascular disease, diabetes mellitus with target organ 
damage or an additional major risk factor, severe chronic kidney disease, or a Systematic Coronary Risk Estimation (SCORE) ≥10%; high risk indicating single risk 
factors (very high BP or cholesterol), or diabetes mellitus without risk factors or target damage, or moderate chronic kidney disease, or SCORE ≥5% and <10%; 
low-moderate risk indicating all remaining patients. 
c Analyzed using Chi-squared test. 
d Data are median (interquartile range) and analyzed using Poisson regression. 
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observations of equal or even better control of BP and HbA1c [11,12,15, 
26] in women compared to men. 
It has previously been reported that women with CVD had higher 
LDL-C levels but were less likely to receive statin therapy than men [13, 
14], and lower statin prescription rates in women compared to men in 
secondary prevention (77.7% vs. 82.8%) have recently been confirmed 
in the European Society of Cardiology EUROASPIRE V registry [27]. 
Similarly, observational data collected in the United States showed that 
women eligible for statin therapy for both primary or secondary pre-
vention were less likely than men to be offered treatment [28] and to 
receive guideline-recommended statin intensity [25,29]. The differences 
in preventive measures targeting LDL-C between women and men could 
have several reasons. First, general practitioners may unconsciously and 
biasedly perceive women to be at lower risk of CVD and thus at lower 
need for preventive measures [14,30]. Second, female sex is a risk factor 
for statin-associated adverse drug reactions such as muscle symptoms 
and new-onset diabetes [31], which may prompt physicians to a less 
frequent assessment and less intensive treatment as observed in our 
study. However, we also found that nonstatin therapies such as ezeti-
mibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) in-
hibitors were less frequently used in women compared with men, 
although the opposite would be expected if adverse effects of statins 
were the main driver of their less frequent prescription. Third, women 
were less frequently studied in clinical trials on statins, leading to an 
evidence gap [32]. However, data from randomized trials on intensive 
statin therapy clearly indicate that women and men derive equal re-
ductions in the risk of cardiovascular events [33,34]. Similarly, a large 
meta-analysis of 27 clinical studies (46,675 women and 127,474 men) 
showed that the proportional reductions in major cardiovascular events 
per 1.0 mmol/L decrease in LDL-C were similar for women and men, as 
were reductions in all-cause mortality with statin therapy [24]. 
The present study adds several novel findings on sex inequalities in 
both screening and treatment of modifiable cardiovascular risk. First, 
our conclusion on disproportionately inferior LDL-C control in women is 
based on age-dependent assessment rates and measured values of the 
three major cardiovascular risk factors amenable to pharmacologic 
therapy in primary as well as in secondary prevention, and thus more 
comprehensive than previous studies [10,11,13]. In fact, risk assessment 
in apparently healthy people (i.e., primary prevention) is relevant for 
cardiovascular outcomes but remains understudied particularly with 
regard to sex inequalities. Second, in contrast to previous observations 
[12,13], we only included patients seen by general practitioners, who 
are largely responsible for cardiovascular prevention in Switzerland. 
This study is the first to investigate sex differences in cardiovascular 
Fig. 1. Sex- and age-dependent risk factor assessment 
in primary and secondary prevention. 
Predicted (continuous line with 95% confidence in-
tervals) and empirical (diamonds) proportions of 
LDL-C (A), BP (B), and HbA1c (C) assessments in 
women (red) and men (blue) per patient year. 
Transparency of diamonds indicates the number of 
patients (maximum to minimum with increasing 
transparency). BP, blood pressure; HbA1c; glycated 
hemoglobin; LDL-C; low-density lipoprotein choles-
terol. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the Web 
version of this article.)   
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Fig. 2. Sex- and age-dependent measured risk factor 
values in primary and secondary prevention. 
Predicted (continuous line with 95% confidence in-
tervals) and empirical mean (diamonds) values for 
LDL-C (A), systolic BP (B), and HbA1c (C) in women 
(red) and men (blue) per patient year. Transparency 
of diamonds indicates the number of patients 
(maximum to minimum with increasing trans-
parency). BP, blood pressure; HbA1c; glycated he-
moglobin; LDL-C; low-density lipoprotein cholesterol. 
(For interpretation of the references to colour in this 
figure legend, the reader is referred to the Web 
version of this article.)   
Table 2 
Sex-dependent measured lipid values and lipid-modifying treatment in primary and secondary prevention.   
Primary prevention Secondary prevention 
Women Men p value Women Men p value 
n 5,562 6,120  264 762  
LDL-C, mmol/L 3.2 (2.5–3.9) 3.0 (2.3–3.7) <0.001a 2.3 (1.7–3.1) 2.0 (1.6–2.6) <0.001a 
HDL-C, mmol/L 1.6 (1.3–1.9) 1.3 (1.0–1.5) <0.001a 1.5 (1.3–1.8) 1.2 (1.0–1.5) <0.001a 
Non-HDL-C, mmol/L 3.8 (3.1–4.6) 3.7 (3–4.5) <0.001a 2.9 (2.3–3.8) 2.7 (2.2–3.3) <0.001a 
Triglycerides, mmol/L 1.3 (0.9–1.9) 1.4 (1.0–2.1) <0.001a 1.4 (0.9–1.9) 1.4 (1.0–2.0) 0.931a 
Total cholesterol, mmol/L 5.5 (4.8–6.3) 5 (4.3–5.8) <0.001a 4.6 (3.8–5.5) 3.9 (3.4–4.6) <0.001a 
Lipid-modifying treatment, %   <0.001b   0.018b 
No treatment 69.9 63.5  15.2 9.2  
Low intensity statin 1.3 1.0  3.4 1.7  
Moderate intensity statin 18.1 18.8  32.6 30.1  
High intensity statin 6.9 12.5  43.9 53.3  
Statin of unknown intensity 2.7 2.7  4.5 3.7  
Ezetimibe 2.5 3.4  16.3 22.4  
PCSK9 inhibitor 0.05 0.02  1.14 1.18  
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9. 
a Data are median (interquartile range) and analyzed using the Wilcoxon rank-sum test. 
b Analyzed using Chi-squared test. 
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prevention in Europe, where primary care settings are particularly 
important, whereas continental differences on recommendations and 
organization on how to assess risk and intervene at the population level 
may exist (i.e., gynecologists or dedicated cardiovascular care facilities 
may play an important role in certain countries). Third, age-adjustment 
was crucial to investigate sex differences, since cardiovascular risk dif-
fers with age between women and men [5,6]. In fact, we could confirm 
that there was a greater age-dependent increase in measured values of 
LDL-C, BP, and HbA1c in women compared to men in primary preven-
tion. The difference was particularly profound for LDL-C levels, which 
were higher in women than in men older than 50 years, while systolic BP 
levels were higher only in women older than 70–75 years and HbA1c 
values remained lower in women during almost the entire observation 
period. 
This study has certain limitations. Given the observational nature of 
our analyses, we cannot completely exclude residual confounding. On 
the other hand, observational studies more likely reflect what is ach-
ieved in routine primary care compared to randomized clinical trials 
[35]. Indeed, our analysis was based on an extensive dataset covering 
almost 60,000 patients from 62 practices, allowing meaningful com-
parisons particularly for patients in primary prevention (n = 56,694), 
whereas results regarding patients in secondary prevention (n = 2,398) 
should be interpreted more cautiously. We could neither account for the 
general practitioners’ judgment of individual patients, nor for patients’ 
preferences, nor for discontinuation of treatments due to real or 
perceived adverse effects. Also, a large proportion of subjects had 
missing risk factor measurement rates, which may partly be attributable 
to missing data in the electronic medical records. Considering that 
current European guidelines recommend cardiovascular risk assessment 
only every 5 years in individuals without risk factors close to thresholds 
mandating treatment [7], the presumably low assessment rates may also 
result from the relatively short 1-year observation period of this study, 
and should therefore be interpreted with caution. In addition, patients 
with hypertension often measure their BP at home, and these 
measurements may not be recorded by general practitioners. However, 
we did not expect that these limitations introduced a significant bias into 
the analysis that primarily focuses on sex differences, since they likely 
apply to both women and men equally. Lastly, even though women may 
also have their BP measured when seeing a gynecologist, cardiovascular 
prevention in Switzerland is largely provided in primary care settings, 
and hence this likely did not introduce a significant bias. 
In conclusion, compared to other modifiable cardiovascular risk 
factors, women in primary care are disproportionally affected by inferior 
control of LDL-C compared to men independent of their cardiovascular 
risk. Improvements in awareness, assessment, and therapy of elevated 
LDL-C may thus be needed to reduce inherent inequalities in prevention 
of CVD between women and men. 
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Table 3 
Sex-dependent measured BP values and antihypertensive treatment in primary and secondary prevention.   
Primary prevention Secondary prevention 
Women Men p value Women Men p value 
n 12,907 12,571  472 1,177  
Systolic BP, mmHg 131 (120–143) 134 (124–145) <0.001a 136 (126–148) 134 (124–145) 0.044a 
Diastolic BP, mmHg 80 (74–88) 82 (77–90) <0.001a 80 (71–85) 80 (72–86) 0.024a 
Antihypertensive treatment, %   <0.001b   0.111b 
No treatment 54.4 50.5  12.3 12.7  
RAAS inhibitor 41.6 46.8  84.3 84.4  
Beta blocker 19.9 18.9  56.8 61.3  
Calcium channel blocker 13.2 13.0  37.9 30.6  
Diuretic 9.8 8.1  29.9 25.8  
BP, blood pressure; RAAS, renin-angiotensin-aldosterone system. 
a Data are median (interquartile range) and analyzed using the Wilcoxon rank-sum test. 
b Analyzed using Chi-squared test. 
Table 4 
Sex-dependent HbA1c values and antidiabetic treatment in primary and secondary prevention.   
Primary prevention Secondary prevention 
Women Men p value Women Men p value 
n 6,867 7,043  287 787  
HbA1c, % 5.6 (5.3–6.2) 5.7 (5.4–6.6) <0.001a 5.9 (5.5–6.7) 6.0 (5.6–6.8) 0.198a 
Antidiabetic treatment, %   <0.001b   0.903b 
No treatment 81.5 72.8  61.7 60.0  
Oral antidiabetics 17.6 25.8  36.6 38.9  
Insulin 5.0 7.5  16.0 14.9  
HbA1c, glycated hemoglobin. 
a Data are median (interquartile range) and analyzed using the Wilcoxon rank-sum test. 
b Analyzed using Chi-squared test. 
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.atherosclerosis.2021.02.024. 
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